Gwenn Hansen - 14 Oct 2025 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Chief Scientific Officer
Signature
/s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen
Issuer symbol
NRIX
Transactions as of
14 Oct 2025
Net transactions value
$0
Form type
4
Filing time
23 Oct 2025, 19:04:57 UTC
Previous filing
30 Jul 2025
Next filing
30 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hansen Gwenn Chief Scientific Officer C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO /s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen 23 Oct 2025 0001817160

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Restricted Stock Units Award $0 +20,000 $0.000000 20,000 14 Oct 2025 Common Stock 20,000 $0.000000 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2 The RSUs will vest on the second anniversary of the date of grant, subject to the Reporting Person's continuous services to the Issuer from the date of grant through such vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
F3 RSUs do not expire; they either vest or are canceled prior to the vest date.